icone plus
Contact Abonnez-vous aux actualités
Autorisation d’accès précoce refusée à la spécialité DUPIXENT (dupilumab).
See also
Décision d'accès précoce
14/11/2024
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
Xwsy0KuQ1K3w2E38
Listen
